Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis Ying Liu, Timothy Vollmer, Eva.

Slides:

Advertisements

Similar presentations

Impact of multiple sclerosis relapse: The NARCOMS participant perspective Molly Nickerson, Stacey S. Cofield, Tuula Tyry, Amber R. Salter, Gary R. Cutter,

Advertisements

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Use of Interferon Beta and Progression.

Volume 57, Issue 3, Pages (March 2010)

Capturing the Costs of End-of-Life Care: Comparisons of Multiple Sclerosis, Parkinson's Disease, and Dementia Paul McCrone, PhD Journal of Pain and.

Transsylvian selective amygdalohippocampectomy in children with hippocampal sclerosis: Seizure, intellectual and memory outcome Anne E. Beaton, Andrew.

The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study Ruth Ann Marrie,

Copyright © 2014 American Medical Association. All rights reserved.

The association between the severity of poststroke depression and clinical outcomes after first-onset stroke in Korean patients Geun-Young Park, M.D.,

Journal of Neuroimmunology

Volume 18, Issue 4, Pages (June 2015)

NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D.

Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers David L. Steed, MD, the.

Patient Baseline Assessment

Copyright © 2005 American Medical Association. All rights reserved.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis.

R. Bove, B. C. Healy, E. Secor, T. Vaughan, B. Katic, T. Chitnis, P

Internet Interventions

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis Anthony T. Reder, Joel F. Oger, Ludwig Kappos, Paul O’Connor,

Symptom Cluster and Quality of Life in Multiple Sclerosis

Copyright © 2003 American Medical Association. All rights reserved.

The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis Joe Datt, Laura Baldock,

Volume 14, Issue 5, Pages (July 2011)

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Volume 64, Issue 5, Pages (November 2013)

Association between Smoking, Passive Smoking, and Erectile Dysfunction: Results from the Boston Area Community Health (BACH) Survey Varant Kupelian,

Volume 2, Issue 2, Pages (February 2015)

Charles D. Gerson, Mary-Joan Gerson

Irritability in a mixed sample of patients with unipolar and bipolar II depression predicts responsiveness to lamotrigine Evyn M. Peters, Rudy Bowen

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Proof-of-principle study of steam ablation as novel thermal therapy for saphenous varicose veins Renate R. van den Bos, MD, Rene Milleret, MD, Martino.

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker Chia-Chi Hsu, MD,

Antidepressant Therapy in Patients Undergoing Coronary Artery Bypass Grafting: The MOTIV-CABG Trial Sidney Chocron, MD, PhD, Pierre Vandel, MD, PhD,

Effect of a Safe Patient Handling Program on Rehabilitation Outcomes

OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial Jörg Wissel,

NMDA-Receptor Antagonists in Neuropathic Pain

Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ranjit John, MD, Yoshifumi Naka, MD,

Capturing the Costs of End-of-Life Care: Comparisons of Multiple Sclerosis, Parkinson's Disease, and Dementia Paul McCrone, PhD Journal of Pain and.

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

Cutaneous sporotrichosis: the old iodide treatment remains effective

Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic.

Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire Bhavik Shah,

Redefining Appropriate Treatment Expectations

Katie M. Phillips, MD, Lloyd P. Hoehle, BA, BS, Regan W

Steven D. Targum, Christopher J. Catania

Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state P.S.

Person-centred maternity care in low-income and middle-income countries: analysis of data from Kenya, Ghana, and India Patience A Afulani, PhD, Beth.

Socioeconomic Status, Race/Ethnicity, and Health Disparities in Children and Adolescents in a Mixed Rural-Urban Community—Olmsted County, Minnesota Kara.

Treatment with 4Jointz reduces knee pain over 12 weeks of treatment in patients with clinical knee osteoarthritis: a randomised controlled trial L.L.

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Psychological factors and their relation to osteoarthritis pain

A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee

Clinical validity of a disease-specific health status questionnaire: The Peripheral Artery Questionnaire Sanne E. Hoeks, MSc, Kim G. Smolderen, MSc,

Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain

Randomized trial of balneotherapy associated with patient education in patients with advanced chronic venous insufficiency Patrick H. Carpentier, MD,

A multicenter randomized controlled trial evaluating balneotherapy in patients with advanced chronic venous insufficiency Patrick H. Carpentier, MD,

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D.

Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic.

Pain assessment in conscious healthy volunteers: a crossover study evaluating the analgesia/nociception index Q. Yan, H.Y. An, Y. Feng British Journal.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Comparative effectiveness of carotid arterial stenting versus endarterectomy Peter W. Groeneveld, MD, MS, Lin Yang, MS, Alexis Greenhut, MPH, Feifei Yang,

Severity assessment in asthma: An evolving concept

Osteoarthritis and Cartilage

NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella Multiple Sclerosis and Related Disorders Volume 11, Pages 18-24 (January 2017) DOI: 10.1016/j.msard.2016.11.005 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Percentage of patients with clinically meaningful worsening in patient-reported physical impact of MS (≥7.5-point worsening in MSIS-29 PHYS score) by study visit. Estimated from a logistic model adjusted for baseline MSIS-29 PHYS score, baseline Beck Depression Inventory-II score, prior IFN beta use (yes, no), and baseline age (≤35, >35 years). a Percent reduction in odds of clinically meaningful worsening. IFN, interferon; IM, intramuscular; MS, multiple sclerosis; MSIS-29, 29-item Multiple Sclerosis Impact Scale; PHYS, physical impact subscale.. Multiple Sclerosis and Related Disorders 2017 11, 18-24DOI: (10.1016/j.msard.2016.11.005) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 Mean change from baseline in MSIS-29 score over time for the (a) MSIS-29 PHYS and (b) MSIS-29 PSYCH. p values represent between-treatment differences and were estimated based on an analysis of covariance model adjusting for baseline MSIS-29 PHYS (or PSYCH) score, baseline Beck Depression Inventory-II score, prior IFN beta use (yes, no), and baseline age (≤35, >35 years). Error bars represent the standard error of the mean. IFN, interferon; IM, intramuscular; MSIS-29, 29-item Multiple Sclerosis Impact Scale; PHYS, physical impact subscale; PSYCH, psychological impact subscale.. Multiple Sclerosis and Related Disorders 2017 11, 18-24DOI: (10.1016/j.msard.2016.11.005) Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Change from baseline in percentage of patients reporting not at all bothered at week 96 for the (a) MSIS-29 PHYS and (b) MSIS-29 PSYCH. IFN, interferon; IM, intramuscular; MS, multiple sclerosis; MSIS-29, 29-item Multiple Sclerosis Impact Scale; PHYS, physical impact subscale; PSYCH, psychological impact subscale.. Multiple Sclerosis and Related Disorders 2017 11, 18-24DOI: (10.1016/j.msard.2016.11.005) Copyright © 2016 The Authors Terms and Conditions

Fig. 4 Mean change from baseline in the (a) EQ-5D health utility index and (b) EQ-5D VAS score. p values represent between-treatment differences and were estimated based on an analysis of covariance model adjusting for baseline EQ-5D health index (or VAS) score, baseline Beck Depression Inventory-II score, prior IFN beta use (yes, no), and baseline age (≤35, >35 years). Error bars represent the standard error of the mean. EQ-5D, EuroQol 5-Dimensions; IFN, interferon; IM, intramuscular; VAS, visual analog scale.. Multiple Sclerosis and Related Disorders 2017 11, 18-24DOI: (10.1016/j.msard.2016.11.005) Copyright © 2016 The Authors Terms and Conditions